AIM ImmunoTech (NYSE:AIM) Issues Earnings Results

AIM ImmunoTech (NYSE:AIM) posted its quarterly earnings results on Thursday. The company reported ($0.08) earnings per share (EPS) for the quarter, meeting the Zacks’ consensus estimate of ($0.08), Fidelity Earnings reports. AIM ImmunoTech had a negative return on equity of 30.48% and a negative net margin of 6,823.39%.

Shares of NYSE AIM opened at $1.96 on Friday. The stock’s 50 day moving average price is $2.12 and its two-hundred day moving average price is $2.39. AIM ImmunoTech has a 52-week low of $0.38 and a 52-week high of $7.11. The company has a debt-to-equity ratio of 0.03, a quick ratio of 50.01 and a current ratio of 50.01.

Several equities research analysts have recently weighed in on AIM shares. Maxim Group reaffirmed a “buy” rating and issued a $5.00 target price on shares of AIM ImmunoTech in a research report on Tuesday, August 18th. TD Securities upped their price objective on AIM ImmunoTech from $4.25 to $5.50 and gave the company a “buy” rating in a research note on Thursday, September 10th.

In related news, CEO Thomas K. Equels bought 12,316 shares of the stock in a transaction dated Thursday, September 3rd. The stock was bought at an average cost of $2.03 per share, with a total value of $25,001.48. Following the completion of the acquisition, the chief executive officer now owns 184,033 shares of the company’s stock, valued at $373,586.99. The purchase was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Corporate insiders own 1.40% of the company’s stock.

About AIM ImmunoTech

AIM ImmunoTech Inc, an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers and immune-deficiency disorders in the United States. The company's products include Alferon N Injection, an injectable formulation of natural alpha interferon to treat a category of genital warts, a sexually transmitted disease; and Ampligen, a drug of macromolecular ribonucleic acid molecule for the treatment of chronic fatigue syndrome.

Featured Article: What can cause a stock to outperform?

Earnings History for AIM ImmunoTech (NYSE:AIM)

Receive News & Ratings for AIM ImmunoTech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AIM ImmunoTech and related companies with MarketBeat.com's FREE daily email newsletter.